


## SKF 83822

<b>Cat. No.:</b>	HY-116874
<b>CAS No.:</b>	74115-08-5
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>22</sub> ClNO <sub>2</sub>
<b>Molecular Weight:</b>	343.85
<b>Target:</b>	Dopamine Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (290.82 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.9082 mL	14.5412 mL	29.0824 mL
	5 mM	0.5816 mL	2.9082 mL	5.8165 mL
	10 mM	0.2908 mL	1.4541 mL	2.9082 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

SKF 83822 is an atypical agonist of dopamine D1 receptor. SKF 83822 activates adenylyl cyclase (AC), but not phospholipase C (PLC). SKF 83822 is also proved to stimulate AC via cAMP production. SKF 83822 can be used for research of schizophrenia [1][2].

#### IC<sub>50</sub> & Target

Rat D<sub>1</sub> Receptor

#### In Vivo

SKF 83822 (25-100 µg/kg; s.c.; single dose after antagonist) produces a strong rotational response in rat in a dose-dependent manner. And it also stimulates strong expression of the IEG products c-Fos, Fra2, Zif/268 and Arc in the deinnervated striatum<sup>[1]</sup>.

SKF 83822 shows significant effects in a moderate and high dose with 0.25 mg/kg and 0.35 mg/kg, respectively, in monkeys. And it (0.15-0.35 mg/kg; s.c.; single dose) induces locomotion but nor inducing dyskinesia. SKF 83822 results in a state of extreme arousal and locomotor activation without stereotypy<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult, male Sprague-Dawley derived rats <sup>[1]</sup>
---------------	--------------------------------------------------------

---

Dosage:	6.25 µg/kg, 25 µg/kg, 50 µg/kg, and 100 µg/kg; with or without 0.5 mg/kg antagonist SCH 23390.
Administration:	SC; single dose, 30 min after antagonist treatment.
Result:	Produced a strong rotational response at 50 µg/kg which was approximately midway between that produced by the 25 and 100 µg/kg doses in the first experiment. Could be inhibited by antagonist of dopamine D1 receptor, SCH 23390.

---

## REFERENCES

---

- [1]. Wirtshafter D. Rotation and immediate-early gene expression in rats treated with the atypical D1 dopamine agonist SKF 83822. *Pharmacol Biochem Behav.* 2007 Mar;86(3):505-10.
- [2]. Peacock L, et al. Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions. *Biol Psychiatry.* 2001 Oct 1;50(7):501-9.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA